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Available online 20 July 2016Malarial parasite P. falciparum, an apicomplexan protozoan has a 23.3 MB nuclear genome and encodes ~5600
transcripts. The genetic diversity of the parasite within and across geographical zones is a challenge to gene ex-
pression studies which are essential for understanding of disease process, outcome and developing markers for
diagnostics and prognostics. Here, we describe the strategy involved in designing a custom P. falciparum 15K
array using the Agilent platform and Genotypic's Right Designmethodology to study the transcriptome of Indian
ﬁeld isolates for which genome sequence information is limited. The array contains probes representing genome
sequences of two distinct geographical isolates (i.e. 3D7 and HB3) and sub-telomeric var gene sequences of a
third isolate (IT4) known to adhere in culture condition. Probes in the array have been selected based on their
efﬁciency to detect transcripts through a 244K array experimentation. Array performance for the 15K array,
was evaluated and validated using RNA materials from P. falciparum clinical isolates. A large percentage (91%)
of the represented transcriptswas detected from Indian P. falciparum patient isolates. Replicated probes andmul-
tiple probes representing the same gene showed perfect correlation between them suggesting good probe per-
formance. Additional transcripts could be detected due to inclusion of unique probes representing HB3 strain
transcripts. Variant surface antigen (VSA) transcripts were detected by optimized probes representing the VSA
genes of three geographically distinct strains. The 15K cross strain P. falciparum array has shown good efﬁciency
in detecting transcripts from P. falciparum parasite samples isolated from patients. The low parasite loads and
presence of host RNA makes arrays a preferred platform for gene expression studies over RNA-Seq.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Malaria imposes a signiﬁcant burden onworld health. Therewere an
estimated 149–303 million cases of infections along with 0.48 million
deaths reported worldwide in the year 2015 [39]. In the year 2014, 1.6onserved hypothetical protein
rotein (PF1280w); PfROM3,
(PF13_0269).
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ullah University of Science and
. This is an open access article undermillion conﬁrmed cases were reported from the 10 malaria endemic
South-East Asian countries, of which, India registered the highest num-
ber of conﬁrmed cases (70%) [39]. Plasmodium falciparum is often con-
sidered the most virulent among the 5 Plasmodium species known to
infect humans. Malaria elimination programs remain challenged due
to the emergence and reemergence of drug resistant parasites and in-
ability to develop an effective vaccine [11,14].
The failure to develop a successful vaccine and emergence of drug
resistant parasites can partly be attributed to the complex life cycle of
the parasite. Interestingly, many basic aspects of its biology, while in
the host, still need to be explored. This has been partially achieved in re-
cent years due to the advancement in techniques like microarray (DNA
microarrays, Protein binding microarrays, SNP microarrays), array-
comparative genomic hybridization (aCGH) [19], RNA-seq [26], ChIP-
chip [9], Chip-seq [3], mass spectrometry techniques [25], transfection
techniques [5], mutagenesis methods [2], gene knock out techniques
[8,20] and imaging techniques. All these techniques have helped in ex-
ploring some fundamental questions, which was not possible earlier.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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before the release of its ﬁrst sequence draft using PCR ampliﬁed inserts
froma P. falciparumDNA library (shotgunmicroarray) or cDNAs [12,21].
Following the release of the ﬁrst draft of P. falciparum 3D7 genome se-
quence fromMalaria Genome Consortium (The Sanger center Plasmodi-
um falciparum Genome Project, Stanford Genome Technology Malaria
Genome Project, TIGR Plasmodium falciparum Genome Database),
many oligonucleotide based whole genome microarrays has been de-
signed, Importantly high density short oligonucleotide (25mer) micro-
array on Affymetrix platform came from Winzeler lab [18] and long
oligonucleotide (70mer) spotted microarray came from DeRisi lab [4].
Upon release of subsequent updates of P. falciparum genome database
annotation, many new versions of microarrays were evolved and uti-
lized various platforms (To see the comprehensive list of P. falciparum
microarrays designed till date, please refer to NCBI's Gene Expression
Omnibus website http://www.ncbi.nlm.nih.gov/geo/.
Use of microarrays has provided new avenues for understanding
expression and regulation of genes at a genome-wide level. DNA mi-
croarrays have been utilized to show the stage speciﬁc temporal ex-
pression pattern of the parasite during its intra-erythrocytic
developmental cycle (IDC) [4,18,21]. Other microarray based studies
have also helped to explore the transcriptional status of genes in
other life cycle stages like gametocyte and sporozoite stages, differ-
ences and commonality of transcriptional programming at a cross
strain level [19], transcripts possibly involved in gametocytogenesis
[32,41], in vivo transcriptional states of the parasite in infected pa-
tients [6], soft-wired transcriptional reprogramming in response to
drug perturbations [23,36] or environmental cues [24] and expres-
sion pattern of variant surface antigens particularly in clinical condi-
tions [37]. Although the microarray technique has helped in
addressing many fundamental questions, its use has been limited
due to its cost and comparatively large amount of starting biological
material required which is a limitation in the case of clinical isolates.
Most of the arrays for P. falciparum have been designed based on a
single reference strain genome (3D7 laboratory strain) [4,13,18].
These arrays have not considered the possibilities of genomic varia-
tions among strains that could limit transcript detection.
A cross strain P. falciparum custom 15K microarray has been de-
signed in a platform, which provides in manyways the ﬂexibility to de-
sign a custom array. This extends from ordering the number of slides,
allowing updation of the microarray design as and when required. Fur-
ther, due to the cRNA ampliﬁcation strategy adopted, the amount of
starting material required makes studies with ﬁeld derived samples
more feasible. The use of ink-jet based in situ synthesized 60mer long
oligonucleotide probes in the selected platform enhances its sensitivity
and due to outstanding spot uniformity, it reduces the inter-array vari-
ability. It has a broad dynamic range of signal intensity and shows low
and uniform background signal [16]. Probes in our 15K cross-strain
array represent the genomes of two geographically distinct strains i.e.
3D7 and HB3 and the var gene sequences of a third strain (IT4). Probes
have been validated using RNAmaterial from Indian P. falciparum clini-
cal isolates in a 244K array format [33] and best probes were chosen for
the 15K array design. The pre-probe selection experiment helped in
identiﬁcation of probes for efﬁcient detection of transcript sequences
ofﬁeld isolates. Here,we report, the further validation of our cross strain
P. falciparum custom 15K arrays using 13 clinical isolates from patients
with uncomplicated/complicated symptoms due to P. falciparum
infection.2. Results and discussion
This study intends to provide validation of data from the custom
cross strain microarray. The overall examination of the microarray
data is presented as a analysis to validate the strength and accuracy of
the array design and procedures.2.1. Probe selection for 15K Plasmodium falciparum cross strain whole ge-
nome GXP microarray
To screen best probes for transcriptome studies of Plasmodium
falciparum Indian ﬁeld isolates for which genome sequence information
is limited, a 244K custom whole genome array was designed on an
Agilent platform with 60mer oligonucleotide probes (Agilent Microar-
ray Design Identity number (AMADID) 024956). Probes represent P.
falciparum 3D7 strain transcript sequences (PlasmoDB v5.3) [1] and
NCBI EST sequences (NCBI 2007). Details about the 244K array can be
found in our previous report [33].
Probe selection for 15K array was carried out by considering only
sense probes representing PlasmoDB transcripts. GE gMedianSignal
(green channel) and GE_rMedianSignal intensity (red channel) for
each probe was collected. Maximum value of the GE green and red
channel intensity of each probe representing a transcript was calculat-
ed, ranked and probe with maximum GE_Median signal intensity se-
lected for each transcript. Probes with signal intensity N96 (~twice the
average background intensity) were taken for consideration (3025
probes). Transcripts for which representing probes did not qualify the
criteria of showing intensity N96, probes were selected based on their
proximity to the 3′ end of the representing sequences. In this way,
5629 probes representing 3D7 transcript sequences were collected
from the 244K array.
2.2. Plasmodium falciparum 15K cross strain whole genome GXP microar-
ray design
We also designed and included probes against sequences of two
other geographically distinct sequenced P. falciparum strains i.e. HB3
and IT4 so as to represent diverse sequences of P. falciparum in the
array. To design a cross strain P. falciparum array, transcript sequences
were collected from PlasmoDB v6.3 for 3D7 strain (5595 transcript se-
quences), from Broad Institute for HB3 strain (5623 transcript se-
quences) and from NCBI for IT4 strain (80 var gene transcript
sequences) and a unique database was made. Total number of se-
quences thus collected were 11,298 out of which 9842 were unique se-
quences (Although sequence similarity was observed between them)
and 1427 transcripts sequences of HB3were identical to 3D7 transcripts
sequences (determined from BLAST results). Probes collected from the
244K array experiment were BLASTed against the database and probes
having only single signiﬁcant hit with any of the strain were selected.
New probes were designed for the transcripts for which no probes
were found, using Agilent eArray tool. In the case of transcripts for
which speciﬁc probes could not be designed, probes having minimum
number of hits were selected (probes with a potential to cross hybrid-
ize) and these were ﬂagged. Criterion for signiﬁcant hit was alignment
of 30 bp or more with N84% identity with the transcript sequence. Al-
though, the criteria for signiﬁcant hit was as mentioned above, 90% of
the probes showed 60 bp alignmentwith 100% identity to the transcript
sequences. All probes, collected and designedwere BLASTed against the
human transcriptome to check for their cross hybridizing potential with
the human transcripts. Potential cross hybridizing probes were re-
moved from the array design. A total of 6362 user deﬁned long oligonu-
cleotide (60mer) probes were designed against the transcript
sequences present in the database. Based on the BLAST results, probes
were annotated as speciﬁc to any one strain (Single signiﬁcant hit with-
in that strain-3D7 speciﬁc/HB3 speciﬁc/IT4 speciﬁc), common in be-
tween any two or more strain (Single signiﬁcant hit within each
strain-3D7 and HB3 or 3D7 and IT4 or HB3 and IT4 or 3D7, HB3 and
IT4) and cross hybridizing probes (multiple signiﬁcant hits within a
strain). Array was re-annotated recently using the PlasmoDB v8.2.
After the re-annotation, the ﬁnal design of the P. falciparum cross strain
whole genome GXP array (AMADID: 024956) is summarized in Supple-
mentary Table S1 and S2. Out of 6362 probes present in the array, 6120
probes can be used against the transcripts of any one of the strain, 194
Fig. 1. Correlation of replicated probes. Signal intensity (log2) from themedian of 13 RNA
samples of replicated probe pairs (6120 pairs; R2 = 0.99).
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after re-annotation. Brieﬂy, 5791 probes representing 5276 3D7 tran-
scripts, 5374 probes representing 5251 HB3 transcripts and 69 probes
representing 43 IT4 var gene transcripts are present in the array. Further
classiﬁcation of the probes based on the speciﬁcity was performed and
there are 691 3D7 speciﬁc probes, 224 HB3 speciﬁc probes and 41 IT4
speciﬁc probes. These probes were designated speciﬁc for these strains,
as they either did not show alignment, or showed multiple transcript
alignments, for the genome of the other strains. 5164 probes are com-
monbetween strains ofwhich, 5077, 13, 6 and 9 can beused in common
between 3D7 and HB3, 3D7 and IT4, HB3 and IT4 and between 3D7,
HB3, and IT4 strain respectively. Of the, 5276 3D7 transcripts which
are represented by speciﬁc probes in the array, 5203 (94%) are protein
coding, 14 of them are non protein coding (NPC), 2 of them are snRNA
coding, 10 of them are r RNA coding and 47 of them are t RNA coding
genes. Because of the dynamic nature of the genome sequence annota-
tion, a few transcripts that were represented by a speciﬁc probe in the
earlier annotation are not represented by any probes in the new anno-
tation. Probes against these transcripts can be designed and incorporat-
ed in the newversion of the array as Agilent provides theﬂexibility in up
gradation of the custom array.
The array also contains 22 probes representing 8 human housekeep-
ing genes and 536 Agilent controls. The total number of features that
were available in the 8 × 15K array after ﬁlling the 536 Agilent control
features was 15,208. Each designed probe (6362 P. falciparum probes
and 22 human probes) was replicated to ﬁll the features. The remaining
2440 blank features were ﬁlled by randomly selected duplicate probes
from the set of probes speciﬁc to any one strain. All the 60mer oligonu-
cleotide probes were designed and synthesized in situ as per algorithms
andmethodologies used byAgilent technologies for 60mer in situ oligo-
nucleotide DNA microarrays.
2.3. Performance of probes to detect transcripts of Plasmodium falciparum
ﬁeld isolates
Probe efﬁciencywas evaluated for its ability to detect the transcripts
of the Indian P. falciparum ﬁeld isolates. Parasite RNA samples (n= 13)
were hybridized to individual arrays. Based on the normalized signal in-
tensity, 5502 probes (90%) were able to detect 91% of 3D7 and 92% of
HB3 transcript sequences in at least one out of thirteen samples ana-
lyzed. Transcripts were not detected by 618 (10%) probes andmay rep-
resent genes which might express in parasite stages not present in the
samples analyzed here or might represent variant surface antigen cod-
ing genes. This point has been analyzed in detail in the next section.
Due to the in situ probe creation process, probes were of high quality
and the background signal was quite low. There are 6120 probes
representing P. falciparum transcripts sequences that are present as du-
plicates in the array. All the duplicate probes showed almost perfect cor-
relation (r= 0.99) between them (Fig. 1).
The array contains 10% of 3D7 genes represented by more than one
probe (1101 probes representing 522 genes) and accuracy of measure-
ments of these individual probes was veriﬁed. Pair wise Pearson corre-
lation of multiple probes representing the same gene was calculated.
Seventy two percent of genes represented by multiple probes and de-
tected in at least 4 out of 13 samples showed average Pearson correla-
tion (r) above 0.8 between the probes representing the same gene.
Percentage of geneswith Pearson correlation between their representa-
tive probes N0.8 was found to increase, if probe detection status in-
creased for number of samples, e.g. increased from 4 samples to 5 or 6
samples (Supplementary Fig. 1). This indicates that the correlation be-
tween probes representing the same transcript is high and multiple
probes which could detect transcripts in the majority of samples can
be taken for further analysis with high conﬁdence level. One of the ex-
amples for genes with multiple probes is the gene encoding DBL like
protein (PF11_0506). This gene is represented by 9 probes out of
which 6 probes were detected in at least 4 samples and showed anaverage Pearson correlation of 0.986 (Fig. 2). Probes representing a tran-
script with low Pearson correlation value may bind to sequence regions
having variations, where one oligonucleotidemay bind to the transcript
efﬁciently in case of a test sample and the others may not. This would
provide in-consistent signal intensity across the samples in comparison
to the efﬁcient binder. In case of such probes, those showing the highest
consistent detection values across samples have been considered.
The frequency of signal distribution of RNA/transcripts showed that
many features werewith low signal intensity, when probes irrespective
of the ﬁltering criteria (detected and not detected probe) were taken
into consideration. After applying the ﬁltering criteria and considering
probes that were detected in at least one sample, many probes with
low signal intensity were removed and the graph showed a bell shaped
appearance adhering to the well accepted frequency distribution of sig-
nal intensities for whole genome expression proﬁle (Supplementary
Fig. 2). The low intensities for many features may be due to low expres-
sion of the genes in the blood stages of the parasite that are normally
present in the peripheral blood of the infected humans from where
the parasite material was isolated. The parasite exclusively expresses
many of the genes that are stage speciﬁc (maximum expression at one
point/stage of its lifecycle and express in low abundant or do not ex-
press in other stages) [4,18].
2.4. Stage speciﬁc expression pattern of detected and undetected transcripts
Developmental stage speciﬁc gene expression proﬁles of this para-
site from culture condition have been reported andmaximum andmin-
imum expression stages formost of the genes have been determined [1,
4,18]. Transcripts, which were not detected and detected in this study,
were analyzed to ﬁnd out the blood stages in which they express max-
imum and minimum [1,4,18]. Transcripts were detected from 4846
genes (91% of the genes represented in the array) in at least 1 sample
out of the 13 samples analyzed (Supplementary Table S3). Majority of
these have been reported to express maximum in G (21%), ER (14%),
M (14%), LR (7%) and ET (13%) stages. Stages in which these genes
expressed minimum were G (27%), ER (25%), M (12%) and LS (10%)
stages (Fig. 3). There were 4.1% genes for which expression data is not
available from the previous studies using microarray (PlasmoDB v8.2)
Fig. 2. Correlation of 6 probes representing antigen 332 encoding gene (PF11_0506). PF11_0506 is represented by 9 probes out of which 6 probeswere detected in at least 4 samples. Pair
wise Pearson correlation was calculated for detected probes. Average Pearson correlation of all the 6 detected probeswas 0.986. Figure shows the expression patterns of all the 6 detected
probes in the 13 RNA samples as 13 data points.
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detect most of the represented transcripts if expressed in a detectable
range.
In this study, 6.9% transcripts of 3D7 strain represented by speciﬁc
probes were not detected (Supplementary Table S4). Investigation of
their expression in the reported data revealed that 29% of these (108
transcripts) expressed maximum in stages like early ring (ER)—5%
(n = 20), late ring (LR)—13% (49) and Gametocyte (G)—11% (39)
which are normally found in peripheral blood of infected patients (Sup-
plementary Fig. 3). We have investigated the probable cause for not de-
tecting these transcripts although they were represented by speciﬁc
probes. We observed that many of these, which expressed maximum
in early ring and late ring stages in culture condition constitutes variant
parasite encoded erythrocyte surface antigens like Plasmodium
falciparum erythrocyte membrane protein 1 (PfEMP1) (n= 5), repeti-
tive interspersed family protein (RIFIN) (n = 14), sub-telomeric vari-
able open reading frame (STEVOR) (n = 5) and Plasmodium
falciparumMaurer's cleft-2 trans membrane domain containing protein
(PfMC-2TM) (n=4). There are 29 genes in the list forwhich expression
data is not available in the PlasmoDBv9.2 (transcripts have not beende-
tected in culture condition usingmicroarray) [1,18]. Many genes which
express maximum in merozoite (M) stage might also express in ring
stage due to possible involvement in linked processes like erythrocyte
invasion and infected erythrocyte remodeling, so we have scanned the
list of genes which expressmaximum in this stage too. In themerozoite
stage, 112 genes from the not detected list have been reported to ex-
press maximum, out of which again riﬁn (n = 54) predominates inFig. 3. Maximum and minimum expression stages of detected transcripts in different
blood stages of the P. falciparum. Blood stages at which each detected transcript was
reported to be expressed maximum and minimum were retrieved from PlasmoDB v8.2.the list. Other genes that are present in the list are genes encoding for
STEVOR (n=8), PfEMP1 (n=3), PHISTa (n=2) and hypothetical pro-
teins (n= 24).
Members of variant surface antigens (PfEMP1, RIFIN and STEVOR)
thought to be expressed in a mutually exclusive pattern where one
member at a time expresses and others shut down. This has been well
established in case of var genes encoding PfEMP1 antigens and might
be the cause for un-detection of these transcripts. This might also hold
true for the other erythrocyte surface antigens (i.e. RIFINs and
STEVORs). Members of riﬁn and stevor gene family were also reported
to transcribe at a later stage of the intra erythrocytic developmental
cycle. Plasmodium helical interspersed sub-telomeric (PHIST) family
genes containing PHIST domains have been clustered into three groups
(i.e. PHISTa, PHISTb and PHISTc). Microarray data from P. falciparum
3D7 strain has shown that PHISTa genes are generally not detectably
transcribed [30]. Genes which expressed in other developmental stages
(early trophozoite (ET), Late trophozoite (LT), early schizont (ES), late
schizont (LS), liver and mosquito stages) and are not found in the pe-
ripheral blood of the infected patients may produce low amounts of
transcripts under certain in-vivo conditions, and are also found in the
not detected transcripts list.2.5. Probes speciﬁc to HB3 strain and transcripts detection
The array contains 288 HB3 strain speciﬁc probes (only can be used
for HB3 strain) representing 282 HB3 transcripts. Out of these 288
probes, 147 probes are speciﬁc to HB3 strain because they did not
show similarity with any of the 3D7 transcript sequences (based on
BLAST results) and 141 probes were assigned as speciﬁc to HB3 strain
because they showed multiple hits against 3D7 transcripts (cross hy-
bridizing probes for 3D7 strain) but showed single hit to any one of
the HB3 strain transcript (Supplementary Table S5). As many as 202
probes representing 196 transcripts were detected in at least one sam-
ple. Of the 147 probes, that are speciﬁc to HB3 (no hits found against
the 3D7 transcripts), 106 probes representing 103 genes were able to
detect transcripts (Supplementary Table S5). Most of these transcripts
code for hypothetical proteins except for some PfEMP1 and RIFINs.
This suggests that variations in the transcript sequences between strains
and transcript of genes that are additional to a strain can be captured by
the array. This would give information about the expression status of
the transcripts that are expressed, but could not be earlier detected
due to strain speciﬁc sequence variability, as most of the arrays relied
on the genome sequence of P. falciparum 3D7 reference strain. This
could be true for studies investigating the in vivo transcriptome status
[6].
Fig. 4. Heat map showing combined hierarchical clustering of differentially regulated
probes in 13 samples. Clustering applied on both samples and probes. Pearson centered
distance matrix and average linkage rule was used. 1260 differentially regulated probes
were included to generate the tree. Hierarchical clustering demarcated total samples
under investigation into two clusters.
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This array is supplemented with probes representing the parasite
genes encoding variant surface antigens of three geographically distinct
strains. Probes in the array represent the var genes of 3D7, HB3 and IT4
strains and riﬁn and stevor genes of 3D7 and HB3 strains. Transcript de-
tection capability of these probes was ascertained.
Based on the 5′ upstream sequence and chromosomal location, the
PfEMP1 proteins in the P. falciparum have been divided into ﬁve groups
(A, B, C, B/A and B/C) [29]. Arrays used in this study contain speciﬁc
probes representing var genes of the three strains (40 var genes of
3D7 strain, 30 of HB3 strain and 34 of IT4 strain) (Supplementary
Table S6). Probes representing var genes were either speciﬁc for one
strain or could be common between strains. All the full var genes were
considered for this analysis and var pseudo genes, var gene fragments
and var like genes were excluded from the analysis, although many of
these are represented by speciﬁc probes. Many var genes that are not
represented by speciﬁc probes are represented by cross hybridizing
probes, where a single probe represents multiple var genes of a strain.
Usually these represent genes from the same var group. Because of the
high sequence similarity between var genes, it is difﬁcult to design 3′ bi-
ased speciﬁc probes for all the members of the var gene family. Tran-
scripts for 35, 3D7 var genes, 25 HB3 var genes and 23 IT4 var genes
could be detected in at least 1 sample by representing probes (Supple-
mentary Table S6). Taking the 3D7 strain as an example, transcripts
were detected frommembers of all the var group represented by probes
but was dominated by var group B sub-family genes.
Joannin et al. [15] grouped 134, 3D7 and 59, HB3 RIFIN protein se-
quences into two groups (97 RIFINs in group A and 37 RIFINSs in
group B for 3D7 and 50 RIFINs in group A and 9 RIFINs in group B for
HB3 strain respectively) [15]. Array contains speciﬁc probes for 80
group A and 19 group B riﬁn genes of 3D7 strain and 43 group A and 9
group B riﬁn genes of HB3 strain. Transcripts were detected from 40,
3D7 riﬁn genes (34 riﬁn group A and 6 riﬁn group B genes) and 27
HB3 riﬁn genes (22 riﬁn group A and 5 riﬁn group B genes) by probes
in at least 1 sample (Supplementary Table S7).
Array contains probes for 26 stevor genes out of 28 genes present in
the P. falciparum 3D7 reference strain [10]. Transcripts were detected
from 14 stevor genes (Supplementary Table S8). Out of 28 stevor genes
reported to be present in the HB3 strain [15], 23 are represented by spe-
ciﬁc probes. Transcripts were detected from 13 of these genes (Supple-
mentary Table S8). The expression of riﬁnswere reported to peak at 12–
27h (ring and trophozoite stages) post invasionwhereas stevorswas re-
ported to peak at 22–32 h (trophozoite and schizont stages) post inva-
sion of merozoites but expression of these geneswas not only restricted
to these stages and might express in other stages too [31]. Probes
representing these VSA gene transcripts could efﬁciently detect the
transcripts although some of them expressed at low levels. It is essential
to detect these transcripts in vivo as their expression might determine
their possible interaction with the host molecules and henceforth the
pathological outcome [22].
2.7. Gene expression proﬁling of clinical isolates
Hierarchical clustering (similarity measure used Pearson centered,
linkage rule used average) of the parasite whole genome expression
proﬁles of 13 samples, segregated parasite samples into two broad clus-
ters (i.e. cluster 1 and cluster 2). Cluster 1 contains 7 samples and cluster
2 contains 6 samples (Fig. 4). Only probes representing the 3D7 strain
were considered for this analysis. Comparison between cluster 1 and
cluster 2 was performed to investigate genes, which differed between
the two clusters. After allowing multiple testing corrections (Benjamini
Hochberg False Discovery Rate) by applying a cut-off of ≥2.0 fold chang-
es based on unpaired statistical t-test, the number of probes that dif-
fered between cluster 1 and cluster 2 were 1260 representing 1214
genes. Of the 1214 genes declared as signiﬁcant, 53% (649) were up-regulated and 47% (564) were down-regulated in cluster 1 compared
to cluster 2 (Supplementary Table S9).
2.8. Real time PCR based validation of few differentially regulated genes
To conﬁrm the microarray results, we examined ﬁve genes by real-
time qPCR. Either Northern blot or qPCR can be performed as an inde-
pendent gene expression proﬁling method to conﬁrm microarray data.
We have chosen qPCR over northern blot because it requires less
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of RNAmaterial we get from clinical samples is very less), very good de-
tection sensitivity, sequence speciﬁcity, large dynamic range as well as
high precision and reproducible quantitation. Five randomly selected
differentially regulated genes were selected for validation. Real time
qPCR results conﬁrmed up-regulation of three genes out of four up-reg-
ulated genes from the microarray analysis (N1 Log2 fold change) and
one gene showed Log2 fold change expression of 0.13 (this did not qual-
ify our criterion considered for designating up-regulated transcript ex-
pression) (Fig. 5). In case of down-regulated gene, a Log2 fold change
expression of −0.70 was observed from qPCR analysis (Fig. 5). Real
time qPCR validated overall expression pattern of selected genes as
seen in the microarray data (Supplementary Fig. 4) (Spearman's rank
correlation = 0.99).
3. Signiﬁcance, utility of the array and concluding remarks
A P. falciparum array designed on Agilent platform and its validation
using RNA material from 3D7 strain has also been reported [16]. Al-
though the array mentioned in this manuscript has utilized the Agilent
platform, it has differences from the already reported Agilent array. The
probes in the latter one were designed against one reference strain
(3D7). In contrast, our array contains probes designed against three dif-
ferent strains (3D7, HB3, IT4) wherever possible. The objective of the
array being detailed herewas to develop the same for usewith ﬁeldma-
terial.We have used standard, certiﬁed cRNAampliﬁcation, labeling and
hybridization protocols of Agilent whereas the previous publication has
used their own protocols. This is very important as our array can be uti-
lized by malaria community by out sourcing the microarray service
from any Agilent certiﬁed microarray service provider. The uniqueness
of our array lies in the fact that multiple probes, representing the se-
quences from 3 P. falciparum laboratory strains of differing geographical
origins, were ﬁrst tested for its efﬁciency to detect transcripts from ﬁeld
isolates. Further, bioinformatics analysis was also performed to remove
probes showing signiﬁcant hit with the human genome. This step is im-
perative for arrays, which are being designed for use with parasite sam-
ples extracted from patients. It is a matter of fact that the already
published array has also been validated for its efﬁciency and has suc-
cessfully been utilized inmany studies for transcriptome analysis of lab-
oratory strains; our array is a good alternate for those handling clinical
isolates with uncharacterized genomes.Fig. 5. Quantitative real-time PCR based validation of 5 differentially expressed genes in
cluster 1 compared to cluster 2. Log2 fold change expression was calculated using
2−ΔΔCt method. Seryl-tRNA synthetase was used as a reference gene. Y-axis represent
genes and X-axis represent normalized fold change expression(mean ± corrected S.D.;
n= 2).In conclusion, a cross-strain P. falciparum array has beendesigned for
in vivo studies utilizing parasite material taken directly from patients.
This array has been used for detection and analysis of the “sense” tran-
scriptome of patient derived parasite material from Western India.
Analysis of the array signals has established the strength of the array de-
sign and procedures adopted. This array has recently been used success-
fully by our group in two studies where we have reported the
expression pattern of speciﬁc sub-groups of var and riﬁn genes in pa-
tients with severe malaria [34] and identiﬁed P. falciparum disease spe-
ciﬁc network modules by generating a P. falciparum speciﬁc weighted
co-expression network [35]. As more sequence information of Indian
P. falciparum strains emerge, additional oligonucleotide probes will be
added to this ﬂexible and evolving cross strain array. In addition to
probes detecting “sense” transcriptome, probes detecting “antisense”
transcriptome could also be included for the documentation of perva-
sive antisense transcription in this parasite. Emerging evidence also sug-
gests the transcription of non-coding RNAs and probes against these
may also be included as this platform provides ﬂexibility in probes in-
clusion and updating array.
4. Materials and methods
4.1. 15K cross-strain P. falciparum microarray
P. falciparum transcript sequenceswere downloaded fromPlasmoDB
v5.3 and NCBI (2007). Eight to ten probes per sequence were designed
in both sense and antisense directionwhich constituted 2,41,399 probes
and additional 2105 Agilent control probes were added to the total
probe list to design a 244K array. P. falciparum RNA samples were hy-
bridized onto it in an Agilent two color format where pooled uncompli-
cated and complicatedmalaria RNA samples were labeled with Cy3 and
Cy5 respectively. Best probes were chosen for 15K array based on the
signal intensities (both Cy3 and Cy5 signal intensities were considered).
Probes representing the same transcript and showing signal intensity
more than twice the back ground were ranked and the top ranked
probe/s was chosen. In some cases, probes showing intensity slightly
lesser than twice the background were not excluded and retained in
the array. Thesewere probes representingmostly the 3′ end of the tran-
script. A total of 5629 probes representing the 3D7 transcript sequences
were collected from the 244K array.
Array was designed using Genotypic Right Design Technology that
enables the user to design the best probes based on GC content, melting
temperature and checking cross hybridization potential across tran-
scriptome as well as genome of a species to create custom microarray
designs. For the P. falciparum cross strain 15K custom array design, the
shortlisted probes from the 244K content were BLASTed against tran-
script sequences from PlasmoDB v5.3 (5595) [1,10] for 3D7 strain,
from the Broad Institute for HB3 strain (5623) and from NCBI for IT4
strain (80 var transcript sequences). Probes having single signiﬁcant
hit within any one of the strain's transcript sequence were selected in
addition to the probes shortlisted by hybridization intensity as men-
tioned above. Additionally, probes were included for transcripts unique
to the PlasmoDB v5.3, HB3 and IT4 strains using Agilent eArray tool
(http://earray.chem.agilent.com). In case of transcripts forwhich specif-
ic probes could not be designed, probes having minimum hits were se-
lected. Criteria for signiﬁcant hit were alignment of 30 bp or more with
N84% identity with the transcript sequence. Although, the criteria for
signiﬁcant hit was as mentioned above, there are 90% of probes in the
array with 60 bp alignment and 100% identity. Probes were BLASTed
against Human transcript sequences and probes cross hybridizing
with the human transcript sequenceswere removed from the list. Strain
speciﬁc speciﬁcity of probes was determined by BLAST analysis and an-
notated accordingly: probes speciﬁc to only one strain, common to two
or all the three represented strains, cross hybridizing to one strain but
speciﬁc to the other strain or cross hybridizing probes. A total of 6362
probes were selected and included in the ﬁnal array design. All the
124 A.K. Subudhi et al. / Genomics Data 9 (2016) 118–125probes were replicated twice and randomly distributed across the array
and empty features were ﬁlled with randomly selected duplicate
probes.4.2. Patients, blood sample collection and processing
Venous blood samples were collected (approximately 5ml) from 13
P. falciparum infected adult patients admitted to S.P. Medical college, Bi-
kaner, India during two transmission seasons, August to October in
2008 and 2009. The patients exhibited symptoms categorized as un-
complicated (n=6) and complicatedmalaria (n=7) as shown in Sup-
plementary Table S10. Criteria for determination of complicated disease
were based on World Health Organization (WHO) guidelines [38]. In-
fection with P. falciparum was conﬁrmed by slide microscopy and
RDTs (OptiMal test; Diamed AG, Cressier sur Morat, Switzerland,
Falcivax test; Zephyr Biomedical System, Goa, India) in the hospital.
All relevant laboratory investigations to rule out any possible cause for
symptoms exhibited (Complicated P. falciparum cases)were done as de-
scribed by Kochar et al. [17]. The samples were collected on informed
consent and approval for sample collection was as per Approval No. F
(Acad) SPMC/2003/2395 of the Hospital Ethics Committee.
Blood was immediately (Within 15–20 min of collection) subjected
to density gradient-based separation (Histopaque 1077, Sigma Aldrich,
USA) to separate the peripheral blood mononuclear cells (PBMCs)
from the infected and uninfected erythrocytes followingmanufacturer's
instructions. Both fractionswerewashed twicewith phosphate buffered
saline and lysed using 4 volumes of Tri-Reagent (Sigma Aldrich, USA)
and stored at−80 °C. Subsequently, samples were transported in cold
chain to the research center at BITS, Pilani, processed and evaluated by
18S rRNA based multiplex PCR and 28S rRNA based nested PCR, to
rule out any possibility of P. vivax co-infection [7,27,28].4.3. RNA sample preparation
Total RNA and DNA were isolated from samples using the
manufacturer's protocol (Tri Reagent, Sigma Aldrich, USA). All RNA
samples were processed on denaturing agarose gel and found to be in-
tact. Total RNA integrity was also assessed using RNA 6000 Nano Lab
Chip on the 2100 Bioanalyzer (Agilent, Palo Alto, CA) following the
manufacturer's protocol. Total RNA purity was assessed by the
NanoDrop® ND-1000 UV–Vis Spectrophotometer (Nanodrop Technol-
ogies, Rockland, USA).4.4. RNA sample labeling, hybridization and data acquisition
The total RNA samples for Gene expression were labeled using
Agilent Quick-Amp labeling Kit (p/n5190-0442). Five hundred nano-
grams from each of the samples were incubated with reverse transcrip-
tion mix at 40 °C and converted to double stranded cDNA primed by
oligodT with a T7 polymerase promoter. The cleaned up double strand-
ed cDNAwas used as template for cRNA generation. cRNAwas generat-
ed by in vitro transcription and the dye Cy3 CTP(Agilent) was
incorporated during this step. The cDNA synthesis and in vitro tran-
scription steps were carried out at 40 °C.
The labeled cRNA samples were hybridized on to a custom P.
falciparum 8 × 15K Array (AMADID: 24956) designed with the assis-
tance of Genotypic Technology Pvt. Ltd., Bangalore, India. 600 ng of
Cy3 labeled cRNA samples were fragmented and hybridized. Fragmen-
tation of labeled cRNA and hybridization were done using the Gene Ex-
pression Hybridization kit of Agilent (Part Number 5188-5242).
Hybridization was carried out in Agilent's Surehyb Chambers at 65 °C
for 16 h. The hybridized slides were washed using Agilent Gene Expres-
sion wash buffers (Part No: 5188-5327) and scanned using the Agilent
Microarray Scanner G2505C at 5 μm resolution.4.5. Pre-processing, data normalization and analysis
4.5.1. Feature extraction
Data extraction from Images, within array normalization, back-
ground subtracted signal intensity calculation and ﬂagging of any outli-
er spots either due to saturation or non-uniformity was done using
Feature Extraction software v 10.5.1.1 of Agilent. Processed signals
from the feature extraction software were used for the analysis. Further
details can be obtained from the feature extraction user guide http://
www.chem.agilent.com.
4.5.2. Data analysis
Feature extracted data was analyzed using GeneSpring GX Version
11.5 software from Agilent. For ﬁnding out differentially regulated
probes, data was ﬁltered by considering all those probes detected in at
least 4 samples out of thirteen samples analyzed. Filtered data was sub-
jected to between arraynormalization using “quantile”method andwas
baseline transformed using median signal intensity of all samples.
Agilent Feature extraction software uses the spot information in the
data to ﬂag the features. Spot information that can be used to ﬂag a fea-
ture as present, marginal or as absent are features that are positive and
signiﬁcant, above background, not uniform, saturated and population
outlier. Features which were positive and signiﬁcant above background
(IsPosAndSignif) established via a 2-sided t-test and well above back-
ground (IsWellAboveBG) were ﬂagged as detected. IsWellAboveBG is
a ﬂagging option which ﬁrst determines if the feature is IsPosAndSignif
and additionally calculates if the background subtracted signal is N2.6
times the background subtracted standard deviation for that feature.
Differentially regulated genes were identiﬁed based on a volcano plot.
Genes were declared as deferentially regulated if they showed fold
change of ≥2 with corrected p value ≤0.05 (after Benjamini Hochberg
based False Discovery Rate correction).
4.6. Data validation by quantitative real-time PCR validation
Total RNA from each sample was treated with DNaseI (Fermentas)
for 30 min at 37 °C. Inactivation of DNase I was performed by adding
1 μl of 50 Mm EDTA per unit of DNase I used and incubated for 10 min
at 65 °C. The absence of DNA in RNA samples was conﬁrmed by no de-
tection of DNA band in 2% agarose gel after 40 cycles of PCR with
seryl-tRNAsynthetase primers. DNase I treated total RNA samples
from cluster 1 and cluster 2 sampleswere pooled in equi-molar amount
separately. First strand cDNA synthesis was carried out using iScript
cDNA synthesis kit (BIO-RAD) in a total volume of 20 μl according to
the manufacturer's recommendations. Quantitative real-time PCR
using IqSYBR green PCR supermix (BIO-RAD) was performed on an
IQ5 real-time PCR cycler (BIO-RAD) using the seryl-tRNAsynthetase
gene as an endogenous control. Fold change expression was calculated
using 2−ΔΔCt method. The cycling parameters used were 1 cycle of
94 °C for 4 min, 55 °C for 2 min and 72 °C for 2.5 min, 35 cycles of 94 °
C for 1.5 min, 55 °C for 1.5 min, and 72 °C for 2 min. All the primers
were designed using NCBI Primer BLAST (Supplementary Table S11)
[40].
Supplementary data associated with this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.gdata.2016.07.006.
Microarray data accession number
The array data are deposited in the Gene Expression Omnibus (GEO)
under accession number GSE54253.
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